Form 4: Solenos CEO Anish Bhatnagar Reports Share Transactions

Solenos Therapeutics CEO Anish Bhatnagar reported the vesting of restricted stock units, subsequent tax withholding, and a significant gift of common stock to family trusts.

Summary

• Anish Bhatnagar, CEO and Director of Soleno Therapeutics Inc. (SLNO), reported changes in his beneficial ownership of common stock.
• On December 15, 2025, 7,620 shares were withheld by the Issuer at a price of $49.95 per share to satisfy tax withholding obligations related to the settlement of restricted stock units (RSUs) that vested on the same date.
• Also on December 15, 2025, Mr. Bhatnagar transferred 100,000 shares of common stock as a gift to two family trusts for the benefit of his descendants, for no consideration.
• Following these transactions, Mr. Bhatnagar's direct beneficial ownership stands at 469,456 shares, some of which are RSUs representing a contingent right to receive common stock.
• Mr. Bhatnagar disclaims beneficial ownership of the shares held by the trusts, as he is not a trustee and does not retain investment or voting control.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions represent routine executive compensation and personal estate planning, with no direct positive or negative implications for the company's operational or financial performance. The reduction in direct ownership is offset by the nature of the transactions (tax payment, gift).

Positives

• The vesting of restricted stock units indicates a portion of executive compensation has been realized, aligning management's interests with shareholder value creation.

Negatives

• The direct beneficial ownership of the CEO decreased by 107,620 shares due to tax withholding and a gift, which reduces his direct stake in the company.

Risks

• No specific risks beyond the nature of the transactions (e.g., tax implications, estate planning) are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction report reflects routine executive compensation and personal estate planning activities, which are common across all industries, including the biotechnology and pharmaceutical sectors where Soleno Therapeutics operates. It does not provide insights into broader industry trends or competitive landscape.

Related Party Transactions

• Anish Bhatnagar transferred 100,000 shares of common stock as a gift to two family trusts for the benefit of his descendants. He disclaims beneficial ownership of these shares.

Stakeholder Impact

• Shareholders: The transactions represent a minor change in the CEO's direct ownership, which is unlikely to have a material impact on the company's stock price or overall shareholder value. The vesting of RSUs is a standard part of executive compensation.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Anish Bhatnagar, CEO, Director, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, RSU Vesting, Stock Gift, Tax Withholding